Abstract:Abstract Extracellular vesicles (EVs) are nanosized heat-stable vesicles released by virtually all cells in the body, including tumor cells and tumor-infiltrating dendritic cells (DCs). By carrying molecules from originating cells, EVs work as cell-to-cell communicators in both homeostasis and cancer but may also represent valuable therapeutic and diagnostic tools. This review focuses on the role of tumor-derived EVs (TEVs) in the modulation of DC functions and on the therapeutic potential of both tumor- and DC-derived EVs in the context of immunotherapy and DC-based vaccine design. TEVs were originally characterized for their capability to transfer tumor antigens to DCs but are currently regarded as mainly immunosuppressive because of the expression of DC-inhibiting molecules such as PD-L1, HLA-G, PGE2 and others. However, TEVs may still represent a privileged system to deliver antigenic material to DCs upon appropriate engineering to reduce their immunosuppressive cargo or increase immunogenicity. DC-derived EVs are more promising than tumor-derived EVs since they expose antigen-loaded MHC, costimulatory molecules and NK cell-activating ligands in the absence of an immunosuppressive cargo. Moreover, DC-derived EVs possess several advantages as compared to cell-based drugs such as a higher antigen/MHC concentration and ease of manipulation and a lower sensitivity to immunosuppressive microenvironments. Preclinical models showed that DC-derived EVs efficiently activate tumor-specific NK and T cell responses either directly or indirectly by transferring antigens to tumor-infiltrating DCs. By contrast, however, phase I and II trials showed a limited clinical efficacy of EV-based anticancer vaccines. We discuss that the future of EV-based therapy depends on our capability to overcome major challenges such as a still incomplete understanding of their biology and pharmacokinetic and the lack of standardized methods for high-throughput isolation and purification. Despite this, EVs remain in the limelight as candidates for cancer immunotherapy which may outmatch cell-based strategies in the fullness of their time.

Extracellular vesicles reshape the tumor microenvironment to improve cancer immunotherapy: Current knowledge and future prospects

Extracellular vesicles remodel tumor environment for cancer immunotherapy

Extracellular vesicles derived from immune cells: Role in tumor therapy

Tumor-derived Extracellular Vesicles: Regulators of Tumor Microenvironment and the Enlightenment in Tumor Therapy

Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy

Extracellular Vesicles and Their Applications in Tumor Diagnostics and Immunotherapy

Extracellular vesicles in the tumor microenvironment: old stories, but new tales

Extracellular vesicles as next generation immunotherapeutics

Extracellular vesicles and the regulation of tumor immunity: Current progress and future directions

Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy

Engineered extracellular vesicles and their mimetics for cancer immunotherapy

Extracellular Vesicles (evs) in Tumor Diagnosis and Therapy

Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells

Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges

Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy

The Role of Extracellular Vesicles in Tumor Therapy and Imaging

Harnessing the therapeutic potential of extracellular vesicles for cancer treatment

Therapeutic Prospects of Extracellular Vesicles in Cancer Treatment

Extracellular Vesicles as Drug Targets and Delivery Vehicles for Cancer Therapy

The Emerging Roles of Extracellular Vesicles As Communication Vehicles within the Tumor Microenvironment and Beyond